Ajanta Pharma Limited has announced that its Board of Directors will convene on November 3, 2025, to deliberate on several key financial matters, including the declaration of the company's first interim dividend for the fiscal year ending March 31, 2026.

Key Points of the Announcement

• Board Meeting Date: November 3, 2025
• Agenda Items:
  • Consider declaring the first interim dividend for FY 2025-26
  • Review unaudited financial results for Q2 and H1 FY 2025-26
  • Potentially fix the record date for dividend payment

Dividend Considerations

The pharmaceutical company has informed the stock exchanges that if an interim dividend is declared, the Board will consider setting November 10, 2025, as the record date for determining shareholder eligibility.

Financial Review

In addition to the dividend deliberation, the Board meeting will focus on reviewing the company's financial performance. The agenda includes:

• Examination of unaudited financial results for the second quarter (Q2) of FY 2025-26
• Review of half-yearly (H1) financial results ending September 30, 2025

Regulatory Compliance

Ajanta Pharma's announcement aligns with regulatory requirements, as stated in their official communication:

"Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2026; and b. fixation of Monday, 10th November 2025 as the Record Date for the payment of interim dividend, if declared."

Investor Implications

Shareholders and potential investors should mark these dates:

Investors are advised to monitor the outcome of this board meeting, as it may impact the company's stock price and provide insights into Ajanta Pharma's financial health and shareholder return policies.

The company has requested the stock exchanges to disseminate this information to all concerned parties, ensuring transparency and compliance with market regulations.

Ajanta Pharma Limited, a prominent player in the pharmaceutical sector, has reported a significant development involving one of its promoters. Ravi Agrawal, a key promoter of the company, has released a pledge on 130,000 shares, as disclosed in a recent regulatory filing.

Pledge Release Details

The company announced that Ravi Agrawal has released the pledge on 130,000 shares of Ajanta Pharma. This action was reportedly undertaken for refinancing purposes, indicating a strategic financial move by the promoter.

Regulatory Compliance

In adherence to the Securities and Exchange Board of India (SEBI) regulations, Ajanta Pharma has duly submitted the prescribed forms detailing this transaction to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). This prompt disclosure underscores the company's commitment to transparency and regulatory compliance.

Implications for Investors

The release of pledged shares by a promoter can be seen as a positive signal by the market. It potentially indicates the promoter's confidence in the company's financial stability and future prospects. However, investors should note that this action is part of a refinancing strategy and should be viewed in the broader context of the company's overall financial position.

About Ajanta Pharma Limited

Ajanta Pharma Limited is a specialty pharmaceutical formulation company known for its presence in domestic and international markets. The company focuses on branded generics in several therapeutic segments and has a strong presence in emerging markets.

This development comes as part of the ongoing financial management strategies of the company's promoters. Shareholders and potential investors are advised to consider this information along with other financial and operational aspects of Ajanta Pharma when making investment decisions.